


Healthcare Industry News: adalimumab)
News Release - October 23, 2006
New Phase III Data Shows Abbott's HUMIRA(R) (Adalimumab) Induced Clinical Remission In Patients With Crohn's Disease Who Lost Response to, or Were Intolerant to, Remicade(R) (Infliximab)
Source: Abbott
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
